NINA COPELAND: Open Payments
NPI 1295093532 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,421 in 115 payments from 20 companies in 2025. Trend: 2023 $51,785 · 2024 $21,620 · 2025 $2,421
Food & beverage: $2,414Speaker / faculty: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $334 |
| REVANCE THERAPEUTICS, INC. | 4 | $323 |
| Arcutis Biotherapeutics, Inc. | 1 | $243 |
| Novartis Pharmaceuticals Corporation | 12 | $237 |
| Lilly USA, LLC | 11 | $216 |
| GENZYME CORPORATION | 6 | $178 |
| Janssen Biotech, Inc. | 10 | $150 |
| Galderma Laboratories, L.P. | 17 | $143 |
| Regeneron Healthcare Solutions, Inc. | 5 | $123 |
| LEO Pharma Inc. | 4 | $93 |
Products named: DAXXIFY, DUPIXENT, Zoryve, COSENTYX, TALTZ, TREMFYA, SKYRIZI, BOTOX.
Industry payments across AR — which companies pay providers there.
